NasdaqGM:ATAIPharmaceuticals
AtaiBeckley Advances Key Depression And Anxiety Programs As Losses Mount
AtaiBeckley (NasdaqGM:ATAI) reported FDA support to advance BPL-003, its proprietary intranasal formulation, into Phase 3 trials for treatment-resistant depression following an End-of-Phase 2 meeting.
The company also released positive topline data from an exploratory Phase 2a study of EMP-01 in social anxiety disorder, indicating efficacy signals with a favorable safety profile.
These updates reflect progress across two key programs in AtaiBeckley’s mental health pipeline that target...